An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan

Keyphrases

• Japan 100%
• Open-label Extension 100%
• Aripiprazole 100%
• Autistic Disorder 100%
• Treatment Duration 33%
• Treatment-related Adverse Events 33%
• Japanese Version 16%
• Daily Dose 16%
• Clinically Significant 16%
• Patient-completed 16%
• Long-term Treatment 16%
• Pediatric Patients 16%
• Placebo 16%
• Long-term Safety 16%
• Vital Signs 16%
• Long-term Efficacy 16%
• Placebo-controlled 16%
• Japanese Pediatric Patients 16%
• Randomized Double-blind 16%
• Influenza 16%
• Change from Baseline 16%
• Subscale Scores 16%
• Prolactin 16%
• Nasopharyngitis 16%
• Somnolence 16%
• New Indication 16%
• Laboratory Values 16%
• ECG Parameters 16%
• Aberrant Behavior Checklist 16%
• Pediatric Autism Spectrum Disorders 16%
• Height Parameters 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Autism 100%
• Aripiprazole 100%
• Adverse Event 33%
• Placebo 33%
• Prolactin 16%
• Rhinopharyngitis 16%
• Somnolence 16%
• Behavior Disorder 16%